Brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) as frontline therapy demonstrates superior modified progression-free survival versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma (HL): The phase 3 ECHELON-1 study Meeting Abstract
| Authors: | Connors, J. M.; Jurczak, W.; Straus, D. J.; Ansell, S. M.; Kim, W. S.; Gallamini, A.; Younes, A.; Alekseev, S.; Illes, A.; Picardi, M.; Lech-Maranda, E.; Oki, Y.; Feldman, T. A.; Smolewski, P.; Savage, K. J.; Bartlett, N. L.; Walewski, J.; Chen, R. W.; Ramchandren, R.; Zinzani, P. L.; Cunningham, D.; Heo, D. S.; Rosta, A.; Josephson, N.; Ruffner, K. L.; Sachs, J.; Liu, R.; Jolin, H.; Huebner, D.; Radford, J. A. |
| Abstract Title: | Brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) as frontline therapy demonstrates superior modified progression-free survival versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma (HL): The phase 3 ECHELON-1 study |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419400061 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.6.6 |
| Notes: | Meeting Abstract: 6 Source: Wos |
Altmetric
Citation Impact
